来氟米特治疗难治性原发性肾病综合征的临床分析
Clinical analysis of leflunomide treatment of refractory primary nephrotic syndrome
摘要
目的：探讨LEF（来氟米特）对原发性难治性肾病综合征的临床疗效情况。方法：选取我院2012年9月-2013年9月收治的64例原发性难治性肾病综合征患者作为研究对象。按照分层法将其分为治疗组及对照组，每组各32例。两组均接受常规激素疗法。对照组加用CTX（环磷酰胺）；治疗组加用LEF。对比两组不良反应发生率及临床疗效情况。结果：①治疗组总有效率96.88%，对照组总有效率81.25%；治疗组总有效率更高（P<0.05）。②治疗组不良反应的发生率显著低于对照组（P<0.05）。结论：应用LEF治疗原发性难治性肾病综合征具有临床疗效好，不良反应少的优点。
Abstract
Objective:To investigate the case of refractory primary nephrotic syndrome, the clinical efficacy of LEF (LEF). Methods:In our hospital in September 2012 September 2013 64 patients were treated with primary nephrotic syndrome refractory study. According to stratification divided into treatment group and control group, 32 cases in each group. Both groups received conventional hormone therapy. The control group were treated with CTX (cyclophosphamide); treatment group LEF. Comparison groups incidence of adverse reactions and efficacy of clinical conditions.Results:The total① treatment group was 96.88%, the total efficiency of the control group (81.25%); treatment group was more efficient (P <0.05). The incidence of adverse reactions② treatment group was significantly lower than the control group (P <0.05).Conclusion:LEF treatment of refractory primary nephrotic syndrome have good clinical efficacy, adverse reactions advantages.
关键词
来氟米特/肾病综合征/临床效果Key words
leflunomide/nephrotic syndrome/clinical effects引用本文复制引用
出版年
2014
NETL
NSTL
万方数据